Precede Bio Insight debuts as a first-of-its-kind product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasmaAACR studies demonstrate the ...
Genes include key targets for next generation precision medicines, such as NECTIN4, B7H4, HER3, DLL3, MUC1, MET, and HER2 and master regulators of transcription, such as AR, ER, FOXA1, ASCL1, and ...
Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...
Rehan Verjee is no stranger to making medicines, having taken several candidates through FDA approvals as the former president of EMD Serono and global head of the Innovative Medicine Franchises at ...
Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers ...
The MarketWatch News Department was not involved in the creation of this content.-- Precede Bio Insight debuts as a first-of-its-kind product enabling genome-wide inference of gen ...
Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNA Genes include key targets for next generation precision medicines, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results